TET2 Antibody (internal region)
Peptide-affinity purified goat antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| IHC, FC, Pep-ELISA |
---|---|
Primary Accession | Q6N021 |
Other Accession | NP_001120680.1, NP_060098.3, 54790, 214133 (mouse) |
Reactivity | Human |
Predicted | Mouse, Dog |
Host | Goat |
Clonality | Polyclonal |
Concentration | 0.5 mg/ml |
Isotype | IgG |
Calculated MW | 223811 Da |
Gene ID | 54790 |
---|---|
Other Names | Methylcytosine dioxygenase TET2, 1.14.11.n2, TET2, KIAA1546 |
Format | 0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
Precautions | TET2 Antibody (internal region) is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | TET2 |
---|---|
Synonyms | KIAA1546 |
Function | Dioxygenase that catalyzes the conversion of the modified genomic base 5-methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC) and plays a key role in active DNA demethylation. Has a preference for 5-hydroxymethylcytosine in CpG motifs. Also mediates subsequent conversion of 5hmC into 5-formylcytosine (5fC), and conversion of 5fC to 5-carboxylcytosine (5caC). Conversion of 5mC into 5hmC, 5fC and 5caC probably constitutes the first step in cytosine demethylation. Methylation at the C5 position of cytosine bases is an epigenetic modification of the mammalian genome which plays an important role in transcriptional regulation. In addition to its role in DNA demethylation, also involved in the recruitment of the O-GlcNAc transferase OGT to CpG-rich transcription start sites of active genes, thereby promoting histone H2B GlcNAcylation by OGT. |
Cellular Location | Nucleus. Chromosome. Note=Localization to chromatin depends upon monoubiquitination at Lys-1299. |
Tissue Location | Broadly expressed. Highly expressed in hematopoietic cells; highest expression observed in granulocytes Expression is reduced in granulocytes from peripheral blood of patients affected by myelodysplastic syndromes. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This antibody is expected to recognize both reported isoforms (NP_001120680.1; NP_060098.3).
References
Acquired mutations in TET2 are common in myelodysplastic syndromes. Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M, Stevens-Linders E, van Hoogen P, van Kessel AG, Raymakers RA, Kamping EJ, Verhoef GE, Verburgh E, Hagemeijer A, Vandenberghe P, de Witte T, van der Reijden BA, Jansen JH, Nature Gen. 2009 Jul 41 (7): 838-42. PMID: 19483684
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.